welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular Dystrophy
study id #: NCT01098708
condition: Duchenne Muscular Dystrophy
Many therapeutic trials in DMD exclude non-ambulatory boys and men. Rate of progression in these non-ambulatory patients has been studied but consensus has not been reached for what measures are most reliable and reproducible. Furthermore, any treatment trial would be expected to demonstrate improved function and improvement in quality of life. Therefore, function, strength, and quality of life must be understood and standardized. While the goal of this proposal is to standardize clinical outcomes for therapeutic trials, careful understanding of the progression of DMD in non ambulatory boys may also lead to better medical treatment.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: March 2010
estimated completion: November 2013
size / enrollment: 50
study description: For Non-ambulatory study, boys must be unable to walk without assistive devices for greater than or equal to one year.
Age at onset of study for non-ambulatory boys and men: greater than or equal to 7 years through age 22 years.
Genetic or biopsy confirmation of dystrophinopathy or clinical diagnosis of DMD with biopsy/genetic confirmation in a primary relative.
- Dystrophin gene mutations that predispose to early onset cardiomyopathy [ Time Frame: 3 years ]
• For Non-ambulatory study, boys must be unable to walk without assistive devices for greater than or equal to one year.
• Age at onset of study for non-ambulatory boys and men: greater than or equal to 7 years through age 22 years.
• Genetic or biopsy confirmation of dystrophinopathy or clinical diagnosis of DMD with biopsy/genetic confirmation in a primary relative.
For Non-ambulatory study, the inability to understand and cooperate with the testing would exclude a subject.
There’s No Straight Line in Drug DevelopmentToday’s FDA disapproval of Sarepta’s...
The time to and determinants of first fractures in boys with Duchenne muscular dystrophyBoys with vertebral fractures (VF) ident...
Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)The purpose of this study is to see whet...
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular DystrophyTo characterize the natural history and ...
Assessment of Cardiopulmonary Function in Duchenne Muscular DystrophyThis study seeks to develop and validate...
Strength Training in Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a d...
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
Corticosteroids for the treatment of Duchenne muscular dystrophyBackground:Duchenne muscular dystrophy (...
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary...FibroGen, Inc., a biopharmaceutical comp...
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...